Parabon NanoLabs, Inc. (PNL) is a nano-pharmaceutical company that develops novel therapeutics using its proprietary Essemblix™ Drug Design Platform – a powerful combination of computer-aided design (CAD) software for designing macromolecules and nanoscale fabrication technology for their production. Our nanoscale development platform gives our scientists the ability to design and construct multi-functional macromolecules from simpler subcomponents, replacing the current paradigm of "drug discovery," which is slow, unpredictable and costly, with a new "drug design" paradigm that is rapid, deliberate and more affordable.
PNL's first products are novel and potent therapeutics for brain, lung, and breast cancer. PNL-24-RD, a targeting compound, is believed to be the first drug compound created using DNA nanostructures.